Drug Trial Radar · NCT06699576
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
448
Planned (sponsor's estimate)
Start
Dec 20, 2024
Primary completion
Dec 30, 2026
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced bone and soft tissue sarcoma.
Conditions
- Osteosarcoma
- Soft Tissue Sarcoma (STS)
Interventions
HS-20093Drug
HS-20093: administered as an IV infusion
AnlotinibDrug
Anlotinib: 12mg once daily (QD) orally
EpirubicinDrug
Epirubicin: administered as an IV infusion
AdebrelimabDrug
Adebrelimab: administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) for combination-treatmentsTime frame: Up to day 21 from the first dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.